Goldman Sachs’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-4,222,280
| Closed | -$166M | – | 6068 |
|
|
2023
Q2 | $166M | Buy |
4,222,280
+3,225,818
| +324% | +$114M | 0.04% | 503 |
|
|
2023
Q1 | $24.2M | Sell |
996,462
-280,962
| -22% | -$6.15M | 0.01% | 1641 |
|
|
2022
Q4 | $27.3M | Buy |
1,277,424
+274,126
| +27% | +$5.85M | 0.01% | 1678 |
|
|
2022
Q3 | $18M | Buy |
1,003,298
+240,487
| +32% | +$3.16M | ﹤0.01% | 1961 |
|
|
2022
Q2 | $7.34M | Buy |
762,811
+342,115
| +81% | +$4.29M | ﹤0.01% | 2791 |
|
|
2022
Q1 | $7.08M | Buy |
420,696
+7,152
| +2% | +$106K | ﹤0.01% | 3021 |
|
|
2021
Q4 | $6.91M | Buy |
413,544
+229,057
| +124% | +$3.75M | ﹤0.01% | 3112 |
|
|
2021
Q3 | $3M | Buy |
184,487
+81,242
| +79% | +$884K | ﹤0.01% | 3817 |
|
|
2021
Q2 | $651K | Buy |
103,245
+16,383
| +19% | +$106K | ﹤0.01% | 5059 |
|
|
2021
Q1 | $536K | Sell |
86,862
-710,546
| -89% | -$4.31M | ﹤0.01% | 5064 |
|
|
2020
Q4 | $5.51M | Buy |
797,408
+450,211
| +130% | +$2.88M | ﹤0.01% | 2931 |
|
|
2020
Q3 | $1.96M | Sell |
347,197
-149,111
| -30% | -$711K | ﹤0.01% | 3580 |
|
|
2020
Q2 | $2.53M | Buy |
496,308
+361,040
| +267% | +$1.5M | ﹤0.01% | 3286 |
|
|
2020
Q1 | $465K | Buy |
135,268
+111,921
| +479% | +$654K | ﹤0.01% | 4260 |
|
|
2019
Q4 | $200K | Sell |
23,347
-6,023
| -21% | -$21.5K | ﹤0.01% | 4896 |
|
|
2019
Q3 | $33K | Buy |
+29,370
| New | +$34.2K | ﹤0.01% | 5079 |
|
|
2019
Q1 | – | Sell |
-13,541
| Closed | -$16K | – | 5537 |
|
|
2018
Q4 | $16K | Sell |
13,541
-26,067
| -66% | -$50.5K | ﹤0.01% | 5161 |
|
|
2018
Q3 | $93K | Sell |
39,608
-2,024
| -5% | -$5.04K | ﹤0.01% | 5158 |
|
|
2018
Q2 | $114K | Sell |
41,632
-71
| -0.2% | -$196 | ﹤0.01% | 5183 |
|
|
2018
Q1 | $114K | Sell |
41,703
-125,164
| -75% | -$363K | ﹤0.01% | 5234 |
|
|
2017
Q4 | $521K | Sell |
166,867
-196,294
| -54% | -$552K | ﹤0.01% | 4799 |
|
|
2017
Q3 | $1.02M | Sell |
363,161
-289,831
| -44% | -$783K | ﹤0.01% | 4551 |
|
|
2017
Q2 | $1.67M | Buy |
652,992
+93,349
| +17% | +$254K | ﹤0.01% | 3980 |
|
|
2017
Q1 | $2.05M | Buy |
559,643
+404,831
| +261% | +$1.71M | ﹤0.01% | 3726 |
|
|
2016
Q4 | $748K | Sell |
154,812
-588,013
| -79% | -$17.5M | ﹤0.01% | 4709 |
|
|
2016
Q3 | $34.3M | Buy |
742,825
+465,232
| +168% | +$26.2M | 0.01% | 1491 |
|
|
2016
Q2 | $14.2M | Sell |
277,593
-5,953
| -2% | -$296K | ﹤0.01% | 2058 |
|
|
2016
Q1 | $12M | Sell |
283,546
-100,542
| -26% | -$5.12M | ﹤0.01% | 2092 |
|
|
2015
Q4 | $30.2M | Buy |
384,088
+94,345
| +33% | +$5.46M | 0.01% | 1465 |
|
|
2015
Q3 | $11.7M | Buy |
289,743
+67,336
| +30% | +$3.57M | ﹤0.01% | 2122 |
|
|
2015
Q2 | $11.6M | Buy |
222,407
+20,745
| +10% | +$1.03M | ﹤0.01% | 2216 |
|
|
2015
Q1 | $9.38M | Sell |
201,662
-68,207
| -25% | -$3.54M | ﹤0.01% | 2344 |
|
|
2014
Q4 | $12.1M | Buy |
269,869
+34,702
| +15% | +$1.46M | ﹤0.01% | 2198 |
|
|
2014
Q3 | $9.15M | Sell |
235,167
-2,453
| -1% | -$96.3K | ﹤0.01% | 2435 |
|
|
2014
Q2 | $10.1M | Buy |
237,620
+12,870
| +6% | +$472K | ﹤0.01% | 2365 |
|
|
2014
Q1 | $8.02M | Buy |
224,750
+200,139
| +813% | +$6.75M | ﹤0.01% | 2558 |
|
|
2013
Q4 | $796K | Buy |
+24,611
| New | +$730K | ﹤0.01% | 4937 |
|
Goldman Sachs's ISEE Position: Q3 2023 in Review
Goldman Sachs sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 4,222,280 shares — an estimated $166M sold.
Goldman Sachs first reported a position in ISEE in Q4 2013 and held it in 37 quarters. The position peaked at $166M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Goldman Sachs reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Goldman Sachs sold 4,222,280 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $166M.
- Goldman Sachs first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 37 quarters.
- Goldman Sachs's IVERIC bio, Inc. Common Stock position peaked at $166M in Q2 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.